Advanced Proteome Therapeutics (STU:0E81) Retained Earnings: €-18.37 Mil (As of Apr. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Advanced Proteome Therapeutics Retained Earnings?

Advanced Proteome Therapeutics STU:0E81 Retained Earnings is €-18.37 Mil as of Apr. 2023.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Advanced Proteome Therapeutics's retained earnings for the quarter that ended in Apr. 2023 was €-18.37 Mil.

Advanced Proteome Therapeutics's quarterly retained earnings increased from Oct. 2022 (€-22.78 Mil) to Jan. 2023 (€-20.99 Mil) and increased from Jan. 2023 (€-20.99 Mil) to Apr. 2023 (€-18.37 Mil).

Advanced Proteome Therapeutics's annual retained earnings declined from Jul. 2020 (€-17.95 Mil) to Jul. 2021 (€-19.45 Mil) and declined from Jul. 2021 (€-19.45 Mil) to Jul. 2022 (€-21.88 Mil).

Advanced Proteome Therapeutics  (STU:0E81) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Advanced Proteome Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Advanced Proteome Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics Retained Earnings Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.47 -18.66 -17.95 -19.45 -21.88

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.07 -21.88 -22.78 -20.99 -18.37

Advanced Proteome Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-18.37 Mil mean?
Advanced Proteome Therapeutics (STU:0E81) has a Retained Earnings of €-18.37 Mil as of Apr. 2023. Retained earnings is the amount of net income not issued to shareholders. View historical data on Advanced Proteome Therapeutics and its competitors.
Is Advanced Proteome Therapeutics' Retained Earnings too high?
Advanced Proteome Therapeutics' current Retained Earnings is €-18.37 Mil.
How does Advanced Proteome Therapeutics' Retained Earnings compare to VRTX and REGN?
Advanced Proteome Therapeutics' Retained Earnings of €-18.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Advanced Proteome Therapeutics and its competitors. Advanced Proteome Therapeutics's current Retained Earnings is €-18.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Proteome Therapeutics stock overvalued right now?
Advanced Proteome Therapeutics (STU:0E81) has a current Retained Earnings of €-18.37 Mil. The current Retained Earnings is €-18.37 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Advanced Proteome Therapeutics (STU:0E81), the current Retained Earnings is €-18.37 Mil as of Apr. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Proteome Therapeutics Business Description

Address 104 8337 Eastlake Drive, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.